학술논문
PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
Document Type
Article
Author
Berlin, M.; Cantley, J.; Bookbinder, M.; Bortolon, E.; Cadelina, G.; Chen, X.; Davenport, K.; DiNicola, D.; Gordon, D.; Hamman, B.D.; Harbin, A.; Haskell, R.; Pizzano, J.; Quinn, C.; Rousseau, E.; Soto, L.; Wang, J.; Broccatelli, F.; Chan, E.W.; Chen, H.; Cheung, T.K.; Januario, T.; Koenig, S.G.; Merchant, M.; Rose, C.M.; Staben, L.R.; Tian, Q.; Ye, C.S.; Ye, X.; Zhou, Y.; Yauch, R.; Dragovich, P.S.; Hole, A.J.; Kerry, P.S.; Pérez-Dorado, I.; Cheng, Y.; He, M.; Li, L.; Sun, H.; Wang, W.; Zhang, P.
Source
In: Journal of Medicinal Chemistry . (Journal of Medicinal Chemistry, 25 January 2024, 67(2):1262-1313)
Subject
Language
English
ISSN
15204804
00222623
00222623